Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ATIS is on the move! -- Ignore unavailable to you. Want to Upgrade?

To: David Lindblade who wrote (1881)	8/21/1999 11:39:00 AM
From: Rick Strange	Read Replies (1) \| Respond to of 2205

David, The FDA has established a committee to investigate the safety issues involved with xenotransplantation and to develop guidelines. Go to: fda.gov search for the key word "xenotransplantation" to read the transcript of the committee meetings and to find FDA guidelines. I reiterate my comments that a human or human based tissue engineered organ, if available, is safer and probably cheaper in the long run than a xenotransplant. It will probably be decades before high demand tissue engineered organs like harts, kidneys and livers are available but I suggest that the safety concerns of xenotransplantation will still remain unresolved by then. We just don't know what pathogens, benign in the host primate or pig, may prove to be lethal to humans.